CBP/β-catenin antagonists have proven efficacious in a wide array of disease and injury models; including pulmonary, renal, hepatic and systemic fibrosis [175,176,177,178], myocardial infarction [179], neuro-development and neuro-degeneration [77,167]. Here, CREBBP is linked to myocardial infarction.